Ilumetri (tildrakizumab)
- Region
- 🇪🇺 EU
- Active substance
- tildrakizumab
- Company
- Almirall, S.A.
- Status
- Authorised
- Therapeutic area
- Psoriasis
- CHMP opinion
- Wed 25 Jul 2018
- EU approval
- Mon 17 Sep 2018
- Application
- EMEA/H/C/004514
- ATC
- L04AC
- Official record
- www.ema.europa.eu
Indication
Ilumetri is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.
Regulatory milestones
No milestones recorded in the last year.
Follow Ilumetri
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.